Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CHIVA2
- 25 Feb 2019 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.
- 25 Feb 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Jun 2020.
- 31 Aug 2018 Biomarkers information updated